{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigqxl6w75dpf3vdd27zdhocwwvqkp5xwa56cxob6lxhimpht3nmqm",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mhwexzeft5k2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigvdwpfcscxkl4lhz62m4ghxafjuocbrcjg3tp3jdnwdslzsxuwxu"
    },
    "mimeType": "image/jpeg",
    "size": 410285
  },
  "path": "/news/2026-03-experts-year-trial-glp-drugs.html",
  "publishedAt": "2026-03-25T19:00:05.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "In new research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May), a global panel of 21 obesity and cancer experts suggest that to test the potential efficacy of the new generation of obesity drugs such as semaglutide and tirzepatide in preventing obesity-related cancer (ORC), a trial of the drugs for some 5,000 participants at high risk of cancer due to their having a cancer pre-cursor condition will provide the required answers.",
  "title": "Experts propose 10-year trial testing GLP-1 drugs to prevent obesity-related cancers"
}